June 29, 2022




U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549


Re:Agile Therapeutics, Inc.
  Registration Statement on Form S-1 (Registration No. 333-264960)
  Concurrence in Acceleration Request


Ladies and Gentlemen:


H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statement on Form S-1 (333-264960) (the “Registration Statement”), hereby concurs in the request by Agile Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 A.M. (Eastern Time), or as soon as practicable thereafter, on July 1, 2022, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.





Securities and Exchange Commission
June 29, 2022
Page 2


Very truly yours,
 By:/s/ Edward D. Silvera
     Name: Edward D. Silvera
     Title: Chief Operating Officer